Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
September 10, 2024 1:08 PM EDT
Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $33.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PoS for VRDN-001/003 to 80% from 66% following positive topline data from the Ph3 THRIVE study (Our Take... More
September 10, 2024 11:41 AM EDT
BTIG analyst Julian Harrison raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $56.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "15wk THRIVE (active TED Phase 3) data show veligrotug (fka VRDN-001) with at least comparable proptosis efficacy vs. Tepezza at 24wk, and veligrotug's placebo-corrected rates of diplopia resolution and hearing... More
